Orange County Business Journal reported that Irvine-based medical technology company Masimo has received FDA fifty-one-k clearance for its smartSedLine brain monitoring technology. The regulatory clearance marks a notable operational milestone for the local entity, establishing the smartSedLine system update as a certified part of its medical device offerings.
The newly cleared smartSedLine technology is specifically engineered to help clinicians assess patient responses to anesthesia during medical procedures. By providing necessary monitoring tools for medical professionals, the technology aims to assist in evaluating how individual patients react under anesthesia.
As part of the recent system update, the smartSedLine technology includes a Patient State Index algorithm. This specific algorithm is incorporated directly into the system to provide faster brain activity readings for clinicians utilizing the technology in clinical settings.
Parent company Danaher oversees Irvine-based Masimo, connecting the local operation to its broader corporate parent. The Irvine-based operations of Masimo continue to develop and secure regulatory clearances and approvals under this established corporate structure.
Regarding the clinical application and medical utility of the technology, Dr. Basil Matta told Orange County Business Journal, "Every patient responds differently to anesthesia, and understanding those individual responses is critical to optimizing depth of sedation and informing care." This clinical perspective highlights the medical context surrounding the smartSedLine technology and its intended use by clinicians assessing patient responses.
This recent regulatory action represents a specific milestone for the company's ongoing regulatory achievements. The clearance represents the seventh FDA approval for Masimo. The accumulation of these regulatory approvals outlines the continued progress of the Irvine-based company.
The smartSedLine system update, incorporating the Patient State Index algorithm for faster brain activity readings, adds to the technological capabilities available to clinicians who must assess patient responses to anesthesia. With parent company Danaher providing organizational backing, Irvine-based Masimo continues its work in developing specialized brain monitoring technology.
The FDA fifty-one-k clearance process allows the smartSedLine technology to be properly utilized by medical professionals seeking to better understand individual patient responses to anesthesia. The inclusion of the Patient State Index algorithm directly supports this clinical objective by facilitating faster brain activity readings for attending medical staff.
Achieving this seventh FDA approval for Masimo underscores the ongoing regulatory milestones reached by the Irvine-based enterprise. The combination of the smartSedLine technology, the Patient State Index algorithm, and the backing of parent company Danaher frames the complete scope of the recent corporate and regulatory update.


